Fluoroquinolone resistance in bacterial isolates from ocular infections: Trend in antibiotic susceptibility patterns between 2005-2020.
Antibiotic resistance
bacteria
endophthalmitis
fluoroquinolone
keratitis
Journal
Indian journal of ophthalmology
ISSN: 1998-3689
Titre abrégé: Indian J Ophthalmol
Pays: India
ID NLM: 0405376
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
entrez:
1
12
2022
pubmed:
2
12
2022
medline:
3
12
2022
Statut:
ppublish
Résumé
To assess the fluoroquinolone resistance pattern and trends among bacterial isolates from ocular infections over a 16-year period and explore alternative antibiotics in fluoroquinolone-resistant strains. In this retrospective, longitudinal study, the microbiology laboratory records of patients with different ocular infections diagnosed at an eye institute in central India from 2005-2020 were reviewed to determine the pattern of fluoroquinolone (ciprofloxacin, ofloxacin, gatifloxacin, and moxifloxacin) resistance. Antibiotic susceptibility testing was done using the Kirby-Bauer disc diffusion method. In 725 Gram-positive bacteria, the resistance of ciprofloxacin, ofloxacin, gatifloxacin, and moxifloxacin was 55.9% (95% confidence interval [CI]: 52.2 - 59.6), 42.7% (95% CI: 39.0 - 46.4), 47.6% (95% CI: 43.9 - 51.3), and 45.6% (95% CI: 41.7-49.5), respectively. In 266 Gram-negative bacteria, the resistance of ciprofloxacin, ofloxacin, gatifloxacin, and moxifloxacin was 57.9% (95% CI: 51.9 - 63.9), 56.0% (95% CI: 49.7 - 62.1), 59.9% (95% CI: 53.8 - 66.0), and 74.3% (95% CI: 68.3 - 80.2), respectively. A declining trend in resistance to ciprofloxacin (P < 0.001), ofloxacin (P < 0.001), and moxifloxacin (P < 0.001) was seen in Gram-positive bacteria, whereas a reduction in resistance to only moxifloxacin (P = 0.04) was seen in Gram-negative bacteria. In fluoroquinolone-resistant Gram-positive bacteria, cefuroxime exhibited the highest susceptibility, whereas in fluoroquinolone-resistant Gram-negative bacteria, colistin exhibited the highest susceptibility. Fluoroquinolone resistance was high among bacteria from ocular infections in central India, but a declining trend in resistance to some of the fluoroquinolones was observed in recent times. Cefuroxime and colistin emerged as alternatives in fluoroquinolone-resistant Gram-positive and Gram-negative bacterial infections, respectively.
Identifiants
pubmed: 36453351
pii: IndianJOphthalmol_2022_70_12_4391_362069
doi: 10.4103/ijo.IJO_1033_22
pmc: PMC9940527
doi:
Substances chimiques
Fluoroquinolones
0
Moxifloxacin
U188XYD42P
Gatifloxacin
L4618BD7KJ
Cefuroxime
O1R9FJ93ED
Colistin
Z67X93HJG1
Ciprofloxacin
5E8K9I0O4U
Ofloxacin
A4P49JAZ9H
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4391-4398Commentaires et corrections
Type : CommentIn
Déclaration de conflit d'intérêts
None
Références
Ophthalmology. 1999 Jan;106(1):80-5
pubmed: 9917785
Optom Vis Sci. 2021 Sep 1;98(9):1113-1121
pubmed: 34510155
J Cataract Refract Surg. 2016 Dec;42(12):1841-1843
pubmed: 28007119
Ophthalmology. 2000 Aug;107(8):1497-502
pubmed: 10919897
Cornea. 2015 Jun;34(6):698-703
pubmed: 25811722
Indian J Ophthalmol. 2019 Jan;67(1):49-53
pubmed: 30574892
Clin Infect Dis. 2009 Dec 1;49(11):1749-55
pubmed: 19857164
Indian J Ophthalmol. 2016 Feb;64(2):153-7
pubmed: 27050354
Clin Ophthalmol. 2020 Jan 29;14:287-297
pubmed: 32099313
Ophthalmology. 1999 Jul;106(7):1319-23
pubmed: 10406614
J Ophthalmol. 2015;2015:813979
pubmed: 26576294
JAMA Ophthalmol. 2020 May 1;138(5):439-450
pubmed: 32271355
Eur J Ophthalmol. 2010 Mar-Apr;20(2):300-5
pubmed: 19924668
JAMA Ophthalmol. 2015 Dec;133(12):1445-54
pubmed: 26502312
Infect Genet Evol. 2019 Apr;69:203-210
pubmed: 30708134
Br J Ophthalmol. 2017 Feb;101(2):108-113
pubmed: 27130916
Indian J Ophthalmol. 2019 Sep;67(9):1508-1509
pubmed: 31436220
Ophthalmology. 1999 Jul;106(7):1313-8
pubmed: 10406613
Clin Infect Dis. 1997 Jan;24 Suppl 1:S67-73
pubmed: 8994781
Clin Microbiol Rev. 2020 May 13;33(3):
pubmed: 32404435
Clin Infect Dis. 2001 Mar 15;32 Suppl 1:S1-8
pubmed: 11249822
PLoS One. 2018 Oct 18;13(10):e0205814
pubmed: 30335799
Surv Ophthalmol. 2004 Mar;49 Suppl 2:S73-8
pubmed: 15028482